ANKURDRUGS

Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Regulations), Section 21A of the Securities Contract (Regulations) Act, 1956, Securities Contract Regulations Rules, 1957 and Bye Laws and Regulations of National Stock Exchange of India Limited (Exchange) it has been decided to delist (withdraw the admission to dealings in) equity shares of the Ankur Drugs And Pharma Limited w.e.f. May 12, 2017 as per SEBI (Delisting of Equity Shares) Regulations, 2009.

Members of the Exchange are hereby informed that the Exchange on December 04, 2016 has issued public notice in the newspaper for compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

Members of the Exchange are hereby informed that trading in the equity shares of Ankur Drugs And Pharma Limited will be suspended w.e.f. September 11, 2013 (i.e. closing hours of trading on September 10, 2013) as the company has failed to respond to the notices of the Exchange for non-compliance with the provisions of listing agreement. It may also be noted that the Official Liquidator of Hon'ble High Court of Bombay, has informed the Exchange that, by an order dated 08-07-2013 passed by Hon'ble High Court of Bombay in C P No: 103 of 2012, Ankur Drugs And Pharma Limited shall be wound up a

Ministry of Corporate Affairs has informed the Exchange regarding an order dated 8/7/2013 passed by the Hon'ble Court in Company Petition No. 103 of 2012 in the matter of Ankur Drugs and Pharma Ltd.

Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the company at its meeting held on June 29, 2013 has taken the following decision: 1) Resignation of Mr. Anil Kumar Khadke as Nominee Director of Central Bank of India w.e.f March 15, 2013 has been accepted by the Board.

Price movement : Significant price movement has been observed in Ankur Drugs And Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Ankur Drugs And Pharma Limited has vide its letter inter-alia stated, "In this connection we have to advice that no activity influencing the price movement of scrip is taking place in the Company. The volatility in the movement of the scrip price is purely market driven and Company in nowhe

Ankur Drugs And Pharma Limited has informed the Exchange that"FCCB holders had filed a petition challanging the scheme of arrangement proposed by the Company before the Hon'ble High Court of the judicature of Bombay. The Hon'ble High Court of the judicature of Bombay vide their order dated May 21, 2013 has stayed the holding of the meeting of Equity Shareholders, Secured Creditors, Unsecured and other Creditors, FCCB holders and Depositors of Ankur Drugs and Pharma Ltd scheduled for Wednesday the 22nd May, 2013 and Friday the 24th May, 2013, respectively till further orders."

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of the Notices for holding meetings of Equity Shareholders, Secured Creditors, Unsecured Creditors, Other Creditors, FCCB Holders and Depositors of the Company to be held on May 22, 2013.

Ankur Drugs And Pharma Limited has informed the Exchange that the Company had received Order from Hon'ble High Court dated March 15, 2013, directing the Company to hold Meeting of Equity Shareholders and Secured Creditors on April 20, 2013 and Meeting of Unsecured and other Creditors, FCCB Holders and Depositors on April 22, 2013 in respect of Scheme of Arrangement and Compromise filed by the Company. Further, the Company had filed an application to Hon'ble Court Bombay for extending time period for holding meeting of Shareholders and Creditors and in this respect, Hon'ble High Court, Bombay h

Ankur Drugs And Pharma Limited has informed the Exchange vide letter dated April 15, 2013 that the Company had received Order from Hon'ble High Court dated March 15, 2013 in respect of Scheme of Arrangement and Compromise filed by the Company. In the said Order Hon'ble High Court have directed the Company to Convene Meeting of Creditors and Shareholders to take approval on Scheme of Arrangement and Compromise as proposed by the Company. The Company is in process of making arrangement to convene meeting of creditors and shareholders.

Ankur Drugs And Pharma Limited has informed the Exchange that the Company has received letter from Central Bank of India informing about the resignation of Mr. Anil Kumar Khadke as Nominee of Central Bank of India. Thus, Mr. Anil Kumar Khadke stands withdrawn as Nominee Director of the Company w.e.f. March 15, 2013. The aforesaid letter will be placed in the forthcoming Board meeting of the Company for approval of Board of Directors and to complete further formalities.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of Minutes of Annual General Meeting of the Company held on December 31, 2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2012.

Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 10, 2012, has taken the following decisions : (1) Letter received from the Nominee Director Mr. A. K. Khadke (Representative of Central Bank of India) requiring the Company to indemnify with costs, expenses and interests for any damage caused to him on account of his being on the board of the Company has been taken on record.

Ankur Drugs And Pharma Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from December 24, 2012 to December 31, 2012 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on December 31, 2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2012.

AAKanksha Securities Private Limited has submitted to the Exchange vide letter dated October 23, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Anupama Furnandu Jain has submitted to the Exchange vide letter dated October 23, 2012 a copy of Disclosure pursuant to Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ankur Drugs And Pharma Limited has informed the Exchange that the Company has made an application for extension of date of Annual General Meeting on August 11, 2012 with Office of Registrar of Companies, Maharashtra. The said application is approved by the Registrar of Companies, Maharashtra and extended date of holding the Annual General Meeting up to December 31, 2012.

Ankur Drugs And Pharma Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled on September 29, 2012 has been cancelled due to unavoidable circumstances.

Ankur Drugs And Pharma Limited has informed the Exchange that the Company has made an application for extension of date of Annual General Meeting on August 11, 2012 with Office of Registrar of Companies, Maharashtra. The said application is approved by the Registrar of Companies, Maharashtra and extended date of holding the Annual General Meeting up to December 31, 2012.

Ankur Drugs And Pharma Limited has informed the Exchange that the meeting of the Board of Directors of the Company scheduled on September 04, 2012 has been cancelled till further notice in this respect.

Ankur Drugs And Pharma Limited has informed the Exchange that the Company in its meeting of the Board of Directors held on August 14, 2012 has passed the resolutions for the following: Appointment of Mr. A. K. Khadke (representative of Central Bank of India) as Nominee Director on the Board of Directors of the Company.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of Revised Result of the Postal Ballot of the Company declared on July 06, 2012.

Ankur Drugs And Pharma Limited has informed the Exchange regarding Result of the Postal Ballot of the Company held on July 06, 2012.

Price movement : Significant price movement has been observed in Ankur Drugs And Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Ankur Drugs And Pharma Limited has vide its letter inter-alia stated, " The Company does not have any price sensitive information to disclose under Clause 36 of the listing agreement".

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of resolution of Board of Directors approving process of Postal Ballot for passing resolutions decided in the Board Meeting along with a copy of Calendar of Events for Postal Ballot.

Ankur Drugs And Pharma Limited has informed the Exchange regarding the outcome of Board Meeting of the Company held on May 14, 2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2012.

Ankur Drugs And Pharma Limited has informed the Exchange the details regarding the voting results of the results of the Postal Ballot held on March 13, 2012.

Ankur Drugs And Pharma Limited has informed the Exchange regarding the Results of the Postal Ballot of the Company declared on March 13, 2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange vide its letter dated February 23, 2012, a copy of the announcement made by the Company relating to its performance.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of the Outcome of the Board Meeting of the Company held on February 01, 2012.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of outcome of Annual General Meeting of the Members of the Company held on September 30, 2011.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of announcement made by the Company in relation to Company's restructuring proposal.

Ankur Drugs And Pharma Limited has informed the Exchange that the Annual General Meeting of the Company will be held on September 30, 2011.

Ankur Drugs And Pharma Limited has informed the Exchange that the Register of Members and the Share Transfer Books of the Company will remain closed from September 23, 2011 to Septmeber 30, 2011 (both days inclusive) for the purpose of the Annual General Meeting of the Company which will be held on September 29, 2011.

Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the Company at its Meeting held on August 12, 2011 has decided on raising funds by issuing following instruments: Type of Instrument : Non Convertible Debentures, Amount raised through instrument: Up to Rs. 100.00 Crores; Type of Instrument: Share Warrants, Amount raised through instrument: Up to Rs.40.00 Crores.

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Ankur Drugs And Pharma Limited has submitted to the Exchange vide its letter dated February 11, 2011, a copy of Corporate Announcement titled "The Company has set up a state of the art facilities at Baddi (Himachal Pradesh)."

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of disclosure under Regulation 8A(4) of SEBI (Substantial Acquisition and Takeover) Regulations, 1997.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of the Results of the Postal Ballot of the Company ' Ankur Drugs and Pharma Limited' declared on December 20, 2010.

Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the Company held on November 14, 2010 has passed the resolutions for the following: 1) The Board has decided to seek the consent of the members through a process of postal ballot under Section 192A of the Companies Act, 1956 for the following: (i) To create charge/ hypothecate / mortgage property of the company in pursuance of Section 293(1) (a) of the Companies Act,1956. (ii) To obtain ratification from the members for the allotment of shares made on May 12, 2009, pursuant to conversion of warrants.(iii) A

Ankur Drugs And Pharma Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Ankur Drugs And Pharma Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 30, 2010.

Ankur Drugs And Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on September 01, 2010 has taken the following decisions: (1) The Annual General Meetings of the Company will be held on September 30, 2010.(2) The Register of Members and the Transfers Books of the Company will be closed from September 23, 2010 to September 30, 2010 (both days inclusive) for the purpose of dividend and AGM.